Bayer's Vitrakvi Is EU’s First Tumor-Agnostic Treatment
The German group's cancer drug is the first to be approved for use in Europe for a wide range of tumors. The principal challenge now is to find eligible patients.
You may also be interested in...
Bayer Bigs Up Vitrakvi In Comparison With Roche's Rozlytrek
In the absence of head-to-head data, the results from a "matching-adjusted indirect comparison" suggest favorable efficacy of the German group's treatment for solid tumors that have a neurotrophic receptor tyrosine kinase gene fusion when compared with competitor Rozlytrek from Roche.
NICE Gives Landmark Nod To Bayer's Vitrakvi
Vitrakvi is the first in a new generation of tumor-agnostic drugs to be made available on the NHS after Bayer and NICE finally reached agreement over pricing and access while more data is collected on its clinical effectiveness.
Bayer's Efforts To Pioneer Tumor-Agnostic Market In Europe Held Back
Bayer’s drive to lead a new market opportunity in Europe for histology-independent cancer agents like Vitrakvi has been set back by interim decisions from the UK’s NICE and Germany’s IQWiG, but there is a now a clear pathway to follow.